Avenue Therapeutics, Inc. (ATXI) stock
Close on Oct 16, 2026Market cap $1.49MP/E –Yield –
Avenue Therapeutics, Inc. reported revenue of $1.40M for fiscal 2025. At the latest close the market valued the company at $1.49M.
Key statistics
Valuation at the latest close; fundamentals over fiscal 2025, balances at Sep 30, 2026
Valuation
- Market cap
- $1.49M
- P/E ratio
- –
- Price to sales
- 1.06
- Price to book
- –
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Revenue
- $1.40M
- Net income
- -$2.79M
- EPS, diluted
- -$0.84
- Book value per share
- -$0.02
- Diluted shares
- 3M
Trading
- Previous close
- $0.43
- Open
- $0.43
- Day's range
- $0.43 – $0.43
- Volume
- 0
- Average volume (20 days)
- 5,575
Market cap history
Month-end market cap since 2017, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Oct 16, 2026. The S&P 500 is measured by the SPY fund.
| Period | ATXI | S&P 500 | Difference | ATXI per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -23.7% | +1.5% | −25.2 pts | ||
| 3 months | +72.0% | +1.9% | +70.1 pts | ||
| Year to date | -36.8% | +12.8% | −49.6 pts | ||
| 1 year | -41.9% | +16.8% | −58.7 pts | ||
| 3 years | -99.1% | +81.5% | −180.6 pts | -78.8% | +22.0% |
| 5 years | -100.0% | +83.0% | −183.0 pts | -80.2% | +12.8% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Press releases
Releases Avenue Therapeutics filed with the SEC as exhibits to Form 8-K or 6-K
- News
- News
- Results
- Results
- Results
- News
About Avenue Therapeutics
Pharmaceutical Preparations
Avenue Therapeutics, Inc. is a specialty pharmaceutical company focused on developing and commercializing therapies for neurologic conditions. The company's primary product candidates include ATX-04, an orally administered selective beta-2 adrenergic agonist under development for the treatment of Pompe disease as an adjunct to enzyme replacement therapy, and intravenous tramadol, a Schedule IV opioid candidate designed for the management of postoperative acute pain in hospital or postsurgical settings. Avenue previously held rights to BAER-101 for epilepsy and panic disorders before divesting the program. Its prospective target end users are treating physicians, surgical practitioners, and patients suffering from rare lysosomal storage disorders or acute postsurgical pain.
Company profile, executives and historyAvenue Therapeutics stock: common questions
What is Avenue Therapeutics's stock price?
ATXI closed at $0.43 on Oct 16, 2026, up 0.00% on the day.
What is Avenue Therapeutics's market cap?
Avenue Therapeutics was worth $1.49M at the close on Oct 16, 2026: the share price times the diluted shares outstanding.
What is ATXI's P/E ratio?
Avenue Therapeutics lost money over the twelve months to Sep 30, 2026 (diluted EPS -$0.84), so it has no meaningful P/E ratio.
How much revenue does Avenue Therapeutics make?
Avenue Therapeutics reported revenue of $1.40M for fiscal 2025.
Does Avenue Therapeutics pay a dividend?
No. Avenue Therapeutics has not paid a cash dividend over the last twelve months.
How has ATXI stock performed over the past year?
Including dividends, ATXI returned -41.9% over the past year, against +16.8% for the S&P 500.
Who are Avenue Therapeutics's competitors?
Companies most similar to Avenue Therapeutics by business, industry and size include OVID, SPRB, VTGN, NEUP, MNOV.
See a number that looks wrong?